Search­ing for new TCR tar­gets, im­munother­a­py start­up emerges with Stan­ford tech, $40M round

In the last decade, im­munother­a­py, which in­volves the us­age of a pa­tient’s own im­mune cells to fight can­cers, has gained great mo­men­tum. In one vari­a­tion, the treat­ment in­volves re­mov­ing a pa­tient’s T cells, a type of white blood cell, and en­abling them to rec­og­nize pro­teins that are on­ly present in can­cer cells. Up­on find­ing its neme­sis the T cells at­tack the can­cer cells. But the ma­jor chal­lenge re­searchers face is dis­cov­er­ing more and more of these pro­teins that are dis­played specif­i­cal­ly on can­cer cells, said Ste­fan Scher­er, CEO of 3T Bio­sciences, a San Fran­cis­co-based biotech.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER